◆ 会议时间：2025年9月20-21日
◆ 会议地点：中国 台湾-台北

◆ 会议简介：

2025年第18届亚太动脉粥样硬化与血管疾病学会(APSAVD)大会将于2025年9月20-21日在中国台湾台北举行，本次会议将汇集科学家、医疗工作者、政策制定者和所有对动脉粥样硬化感兴趣的相关人士。

亚太动脉粥样硬化与血管疾病学会(APSAVD成立于1996年，其宗旨是为该地区对动脉粥样硬化感兴趣的科学家和临床医生提供一个分享交流宣有关该领域最新信息的论坛。未经本站许可禁止复制转载镜像本站任何内容—领域国际医学会议网(lingyuint.com)。

APSAVD Congress 2025
18th Asian Pacific Society of Atherosclerosis and Vascular Disease Congress 2025

Date: September 20 - 21, 2025
Venue: Taipei, Taiwan, China

Organised By：
aiwan Society of Lipids and Atherosclerosis
Asian-Pacific Society of Atherosclerosis and Vascular Diseases (APSAVD)

摘要征文投稿：

Abstract Category (Oral/ Poster)

• Epidemiology of ageing, vascular disease, dyslipidemia or metabolic syndrome
• Basic science research of atherosclerosis, endothelium, inflammation, microcirculation or hrombosis/hemostasis
• Cardiometabolic disease: basic / translational science and clinical research
• Familial hypercholesterolemia: basic / translational science and clinical research
• Imaging in atherosclerosis and cardiovascular disease
• Lipids and lipoprotein metabolism: basic / translational science and clinical research
• Microbiota and nutrition: basic / translational science and clinical research
• Novel interventional therapies for atherosclerosis, vascular disease or metabolic disorders
• Vascular diseases and thrombosis: clinical science
• Big data and precision medicine

General Policy

• The user who submitted the abstract to the submission system would be recognized as the Presenting Author. The presenting author of an accepted abstract (oral and poster) must register and pay the registration fees no later than July 31, 2025 to ensure the rights for the presentation.
• Abstracts must be original and may only be permitted from local congresses, will not be considered if previously presented at international congresses. The accepted abstracts will be published in the Abstract Book.
• Presenting Authors of accepted abstracts MUST be registered, even if they are a student and be responsible for all expenses incurred in the production of their presentations, travel and accommodation during the Conference. Each Presenting Author can submit UNLIMITED abstracts and can also be a co-author of another abstract.
• It is the author’s responsibility to submit a correctly edited and accurate abstract. Any errors in spelling, grammar or scientific fact will be reproduced as typed by the author. Abstracts will be rejected if they contain no data or if the English is unacceptable. All Presenting Authors will receive detailed presentation guidelines when the abstract has been accepted.
• Acknowledgement of the receipt of abstract submission will be sent to the Presenting Author’s email address immediately upon submission. The Presenting Author will receive all correspondence regarding the abstract status, presentation type, date and time, via the email that is provided in the abstract submission.

Submission Guidelines

The abstract must be written and presented in English. Each abstract can only be submitted once. The same abstract cannot be submitted for consideration in different award prize/paper categories. Please read the following instructions carefully before preparing your abstract.

The title of the Abstract:
a. Capitalize all principal words (nouns, verbs, adjectives, etc.). Do not capitalize articles, prepositions, or conjunctions when they fall in the middle of a title.
b. NO full stop (or period) at the end and NO underlining.

The Body of the Abstract:
a. Maximum of 300 words. (If attach one table OR one figure OR one image per abstract)
b. Maximum of 500 words. (No attachment.)
c. Only one (1) table/ graph/ image can be submitted as a part of abstract. The maximum file size is 10 MB.
d. References (maximum of 2) can be included in the body of the text.

Abstracts should be structured as followed:
Background
Method
Results
Conclusion

Note:
1. Authors are advised to ensure the accuracy of the submitted abstracts. Any mistakes in literature or scientific facts will be published as what is typed.
2. All authors named in the abstract have agreed to its submission for presentation and publish at the 2025 APSAVD Congress and that the authors are familiar with and agree with the stated results.

This abstract conforms to all the 2025 APSAVD Congress Abstract Rules and Procedures.
The Scientific Program Committee of the 2025 APSAVD Congress reserves the right to accept or refuse an abstract, to designate abstracts either oral or poster presentation and to choose a suitable session for the abstract.

Dear Esteemed Colleagues, Distinguished Guests, and Friends,
It is with great pleasure and honor that we welcome you to the 18th Asian Pacific Society of Atherosclerosis and Vascular Disease Congress (2025 APSAVD Congress), taking place at the Taipei International Convention Center (TICC) in the vibrant city of Taipei, Taiwan, on September 20-21, 2025.
This congress serves as a premier platform for experts, researchers, and healthcare professionals from across the globe to converge, share, and exchange the latest scientific advancements, clinical practices, and innovations in the field of atherosclerosis and vascular disease. We are privileged to host a distinguished lineup of speakers and presenters who will deliver insightful lectures, engage in thought-provoking discussions, and inspire groundbreaking ideas.
Taipei, renowned for its rich cultural heritage, cutting-edge technology, and world-class hospitality, provides an exceptional backdrop for this significant event. We hope you will take the opportunity to explore the city's unique blend of tradition and modernity, savor its exquisite cuisine, and experience the warmth of its people.
We extend our deepest gratitude to the organizing committee, sponsors, and all participants for their unwavering support and dedication. Your contributions are invaluable in making this congress a resounding success.
We cordially welcome your presence, and wish you an enjoyable experience at 2025 APSAVD Congress.
Yours sincerely,

Ping-Yen Liu, M.D., Ph.D.

Congress President, 2025 APSAVD

注册费：

International

◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。